Implantica presents the third quarter 2020 on November 18, at 10:30 CET

Report this content

Implantica invites investors to a presentation of the third quarter 2020 at 10:30 a.m. CET on November 18. The interim report for the third quarter will be published at 8:00 a.m. CET on the same day.

The presentation will be in English via a conference call or audio webcast:

Conference call dial-in

  • Sweden: +46850558369
  • United Kingdom: +443333009260
  • United States: +18338230587

Webcast

Speakers

  • CEO Peter Forsell
  • CFO Andreas Öhrnberg
  • VP Operations & IR Nicole Pehrsson
 

For further information, please contact:

Nicole Pehrsson, Investor Relations
Telephone (CH): +41 (0)79 335 09 49
nicole.pehrsson@implantica.com

Implantica is listed on Nasdaq First Premier North Growth Market in Stockholm.

The company's Certified Adviser is FNCA Sweden AB, +46 (0)8 528 00 399, info@fnca.se

The information was sent for publication, through the agency of the contact person set out above, on November 12, 2020 at 14:00 CET.

 

About Implantica

Implantica is a medtech group dedicated to bringing advanced technology into the body. Implantica’s lead product, RefluxStop™, is a CE-marked implant for the prevention of gastroesophageal reflux that will potentially create a paradigm shift in anti-reflux treatment as supported by successful clinical trial results. Implantica also focuses on eHealth inside the body and has developed a broad, patent protected, product pipeline based partly on two platform technologies: an eHealth platform designed to monitor a broad range of health parameters, control treatment from inside the body and communicate to the caregiver on distance and a wireless energising platform designed to power remote controlled implants wirelessly through intact skin. Implantica is listed on Nasdaq First North Premier Growth Market (ticker: IMP A SDB). Visit www.implantica.com for further

Subscribe

Documents & Links